A Paradoxical Role for Regulatory T Cells in the Tumor Microenvironment of Pancreatic Cancer
- PMID: 36010856
- PMCID: PMC9405872
- DOI: 10.3390/cancers14163862
A Paradoxical Role for Regulatory T Cells in the Tumor Microenvironment of Pancreatic Cancer
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is considered to be a poorly immunogenic cancer type that combines a low mutation burden with a strong immunosuppressive tumor microenvironment. Regulatory T cells (Tregs) are major drivers of immune suppression but their prognostic role, particularly in gastrointestinal malignancies, remains controversial. Lymphocytic infiltration in 122 PDAC samples was assessed by multispectral immunofluorescence with anti-Keratin, -CD3, -CD8, -FOXP3 and -CD163 antibodies. Differential infiltration by Tregs was analyzed in the context of transcriptomic profiles that were available for 65 tumors. High infiltration of CD3+CD8- (mainly CD4+) T cells and, especially, of the subset expressing FOXP3 (Tregs) was associated with improved patient survival, whilst cytotoxic CD3+CD8+ T cell infiltration did not have an impact on overall survival. Transcriptomic analysis revealed three signatures in PDAC tumors comprising of epithelial-mesenchymal transition (EMT)/stromal, metabolic, and secretory/pancreatic signature. However, none of these signatures explained differences in Treg infiltration. We show that Tregs associate with improved overall survival in PDAC patients. This effect was independent of cytotoxic T cell infiltration and the transcriptomic profiles of their respective tumors. These findings provide a new layer of complexity in the study of PDAC tumor microenvironment that must be considered when developing immunotherapeutic interventions for this disease.
Keywords: pancreatic ductal adenocarcinoma (PDAC); prognosis; regulatory T cells (Treg); tumor infiltrating lymphocytes (TIL); tumor microenvironment (TME).
Conflict of interest statement
The authors declare no conflict of interest.
Figures


References
-
- Antonia S.J., Borghaei H., Ramalingam S.S., Horn L., De Castro Carpeno J., Pluzanski A., Burgio M.A., Garassino M., Chow L.Q.M., Gettinger S., et al. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: A pooled analysis. Lancet Oncol. 2019;20:1395–1408. doi: 10.1016/S1470-2045(19)30407-3. - DOI - PMC - PubMed
-
- Schadendorf D., Hodi F.S., Robert C., Weber J.S., Margolin K., Hamid O., Patt D., Chen T.T., Berman D.M., Wolchok J.D. Pooled Analysis of Long-Term Survival Data from Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J. Clin. Oncol. 2015;33:1889–1894. doi: 10.1200/JCO.2014.56.2736. - DOI - PMC - PubMed
-
- Von Pawel J., Bordoni R., Satouchi M., Fehrenbacher L., Cobo M., Han J.Y., Hida T., Moro-Sibilot D., Conkling P., Gandara D.R., et al. Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study. Eur. J. Cancer. 2019;107:124–132. doi: 10.1016/j.ejca.2018.11.020. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials